Latest feature

Single-dose radiotherapy transforms breast cancer patient care
Our clinicians have transformed breast cancer care by developing a single-dose radiotherapy treatment to be delivered in the same operation as tumour surgery.
The Surgical & Interventional Group is part of UCL's accredited Comprehensive Clinical Trials Unit. Located in Bloomsbury, London, we specialise in providing support to run studies led by surgical and interventional researchers.
Working with clinicians, statisticians, qualitative researchers, health economists, and patient and public representatives (PPI), we provide expertise and support for the design and conduct of high-quality clinical studies aimed at guiding clinical practice.

Our services
We provide a range of services for designing and conducting high-quality clinical studies, from protocol development and safety to data and trial management.

Clinical trials
Surgical & Interventional Group (formally SITU) mainly carries out surgeon-led trials, specialising in pragmatic phase III trials, which are practice changing.
GDPR and use of data
UCL uses personally identifiable information to conduct research to improve health, care, and services. As a publicly funded organisation, we must demonstrate that our research serves the interests of society and that it is in the public interest when we use personally identifiable information. To safeguard your rights, we will use the minimum personally identifiable information possible.
When you agree to take part in a research study, we will use your data in the ways needed to conduct and analyse the research study. Your rights to access, change or move your information are limited, as we need to manage your information in specific ways for the research to be reliable and accurate.
If you wish to raise a complaint on how we have handled your data, you can contact our Data Protection Officer (data-protection@ucl.ac.uk). If you are not satisfied with our response or believe we are processing your personal data in a way that is not lawful, you can contact the Information Commissioner’s Office (ICO).
Feature

PIT-STOP Trial announced
The PIT-STOP trial from UCL Eastman investigates the effect of combining two medications to reduce soft tissue fibrosis of the mouth and throat in head and neck cancer survivors.
Publications
- Kasivisvanathan, V., Emberton, M., Moore, C.M. et al. for the PRECISION Study Group Collaborators (2018). MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. The New England Journal of Medicine.
- ATAC Trialists' Group, Forbes JF, Cuzick J, Buzdar A, et al. (2008). Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. The Lancet Oncology, Vol. 9, Issue 1, pp. 45-53.
- Vaidya J.S., Wenz F., Bulsara M., Tobias J.S. et al. on behalf of the TARGIT trialist's group (2014). Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. The Lancet, Vol. 383, Issue 9917, pp. 603-613.
- Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group (1996). Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. JNCI: Journal of the National Cancer Institute, Vol. 88, Issue 24, pp. 1834–1839.
- Fabes J, Ambler G, Shah B, Williams NR, Martin D, Davidson BR, Spiro M. Protocol for a prospective double-blind, randomised, placebo-controlled feasibility trial of octreotide infusion during liver transplantation. BMJ Open. 2021 Dec 2;11(12): e055864.
- Treasure T, Farewell V, Macbeth F, Batchelor T, Brew-Graves C, et al. The Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) burden of care study: Analysis of local treatments for lung metastases and systemic chemotherapy in 220 patients in the PulMiCC cohort. Colorectal Dis. 2021 Nov;23(11): 2911-2922.
- Vaidya JS, Bulsara M, Baum M, Wenz F, Massarut S, Pigorsch S, et al. New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer. Br J Cancer. 2021 Aug;125(3): 380-389.
- Dinneen E, Haider A, Grierson J, Freeman A, Williams NR, Brew-Graves C, et al. NeuroSAFE frozen section during robot-assisted radical prostatectomy: peri-operative and histopathological outcomes from the NeuroSAFE PROOF feasibility randomized controlled trial. BJU Int. 2021 Jun;127(6): 676-686.
- Orczyk C, Barratt D, Brew-Graves C, Peng Hu Y, Williams NR, Emberton M, et al. Prostate Radiofrequency Focal Ablation (ProRAFT) Trial: A Prospective Development Study Evaluating a Bipolar Radiofrequency Device to Treat Prostate Cancer. J Urol. 2021 Apr;205(4): 1090-1099.
- Brew-Graves C, Farewell V, Monson K, Milošević M, Williams NR, et al. Pulmonary metastasectomy in colorectal cancer: health utility scores by EQ-5D-3L in a randomized controlled trial show no benefit from lung metastasectomy. Colorectal Dis. 2021 Jan;23(1): 200-205.
- Milosevic M, Edwards J, Tsang D, Dunning J, Shackcloth M, Batchelor T, et al. Pulmonary Metastasectomy in Colorectal Cancer: updated analysis of 93 randomized patients - control survival is much better than previously assumed. Colorectal Dis. 2020 Oct;22(10): 1314-1324.
- Vaidya JS, Bulsara M, Baum M, Wenz F, Massarut S, Pigorsch S, et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ. 2020 Aug 19;370: m2836.
- Vaidya JS, Bulsara M, Saunders C, Flyger H, Tobias JS, Corica T, et al. Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival: Long-term Results From the TARGIT-A Randomized Clinical Trial in Early Breast Cancer. JAMA Oncol. 2020 Jul 1;6(7): e200249.
- Tan WS, Teo CH, Chan D, Ang KM, Heinrich M, Feber A, Sarpong R, Williams N, Brew-Graves C, Ng CJ, and Kelly J. Exploring patients' experience and perception of being diagnosed with bladder cancer: a mixed-methods approach. BJU Int. 2020 May;125(5): 669-678.
- Banerjee SM, El-Sheikh S, Malhotra A, Mosse CA, Parker S, Williams NR, MacRobert AJ, Hamoudi R, Bown SG, and Keshtgar MR. Photodynamic Therapy in Primary Breast Cancer. J Clin Med. 2020 Feb 10;9(2).
- Martin DS, Brew-Graves C, McCartan N, Jell G, et al. (2019). Protocol for a feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. BMJ Open.
- Kasivisvanathan V, Rannikko AS, Borghi M, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M and Moore CM, for the PRECISION Study Group Collaborators. (2018). MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis' The New England Journal of Medicine.
- Grey A, Scott R, Charman S, van der Meulen J, Frinking P, Acher P, Brew-Graves C, et al. (2018). The CADMUS trial ‐ Multi‐parametric ultrasound targeted biopsies compared to multi‐parametric MRI targeted biopsies in the diagnosis of clinically significant prostate cancer. Contemp Clin Trials.
- Williams, NR, Kurylcio A, Jankiewicz M, Romanek J, Polkowski W, Michalopoulos NV & Keshtgar MR (2017). Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: Objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology, 38 (6), 867-870.
- Reis S, Gazinska P, Hipwell J, Mertzanidou T, Naidoo K, Williams N, Pinder S, Hawkes DJ (2017). Automated Classification of Breast Cancer Stroma Maturity from Histological Images. IEEE Trans Biomed Eng.
Hear from experts and patients
Professor Jayant Vaidya and a trial patient, the writer Marcelle Bernstein, speak about TARGIT-IORT at a breast cancer event held at the Royal Society.
Contact
Third floor
Charles Bell House
43-45 Foley Street
London
W1W 7JN

Surgical Interventional Group
Click to email. situ.trials@ucl.ac.uk Click to call. +44 (0)20 7679 9280